3692 HANSON
1. Behavior, abbreviation EMA35 test and Horizontal Line
2. The stock chart is stronger than the INDEX
3. Operating results grow in the second half of 2023 after partnering with allies, allowing sales to grow rapidly.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.10 EUR
420.10 M EUR
1.30 B EUR
1.11 B
About HANSOH PHARMACEUTICAL GROUP CO LTD
Sector
CEO
Hui Juan Zhong
Headquarters
Shanghai
Website
Founded
2015
FIGI
BBG00PGLT3N7
Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. Its products include oncology, anti-infective, anti-diabetic, gastrointestinal, and cardiovascular drugs. The company was founded by Hui Juan Zhong on December 2, 2015 and is headquartered in Shanghai, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange HANSOH PHARMAC. HD-,00001 stocks are traded under the ticker 3KY.
We've gathered analysts' opinions on HANSOH PHARMAC. HD-,00001 future price: according to them, 3KY price has a max estimate of 3.56 EUR and a min estimate of 2.13 EUR. Watch 3KY chart and read a more detailed HANSOH PHARMAC. HD-,00001 stock forecast: see what analysts think of HANSOH PHARMAC. HD-,00001 and suggest that you do with its stocks.
Yes, you can track HANSOH PHARMAC. HD-,00001 financials in yearly and quarterly reports right on TradingView.
HANSOH PHARMAC. HD-,00001 is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
3KY earnings for the last half-year are 0.06 EUR per share, whereas the estimation was 0.05 EUR, resulting in a 17.95% surprise. The estimated earnings for the next half-year are 0.03 EUR per share. See more details about HANSOH PHARMAC. HD-,00001 earnings.
HANSOH PHARMAC. HD-,00001 revenue for the last half-year amounts to 835.48 M EUR, despite the estimated figure of 800.87 M EUR. In the next half-year revenue is expected to reach 695.36 M EUR.
3KY net income for the last half-year is 353.02 M EUR, while the previous report showed 249.21 M EUR of net income which accounts for 41.66% change. Track more HANSOH PHARMAC. HD-,00001 financial stats to get the full picture.
HANSOH PHARMAC. HD-,00001 dividend yield was 1.35% in 2023, and payout ratio reached 34.83%. The year before the numbers were 0.67% and 19.69% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 10, 2024, the company has 9.12 K employees. See our rating of the largest employees — is HANSOH PHARMAC. HD-,00001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HANSOH PHARMAC. HD-,00001 EBITDA is 608.76 M EUR, and current EBITDA margin is 30.46%. See more stats in HANSOH PHARMAC. HD-,00001 financial statements.
Like other stocks, 3KY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANSOH PHARMAC. HD-,00001 stock right from TradingView charts — choose your broker and connect to your account.